No image published for this recall

No image published for this recall

Simplexa covid-19 direct assay

Official notice

10 Jan 2022

Last checked

10 Jan 2022

Medium riskHealth Canada

An official Health Canada notice concerns Simplexa covid-19 direct assay. It was recently internally identified that five (5) lots of Simplexatm COVID-19 direct (Ref MOL4150) were shipped to Canada that had been manufactured with the recombinant hot start polymerase produced by Diasorin S.P.A. Instead of the enzyme from an external supplier. While the validation for the material made by Diasorin S.P.A. Had been successfully completed, the change had not yet been approved by Health Canada for use in products shipped to Canada patient results are not impacted by this compliance related issue. Recall start date: Jan 7, 2022 Published 2022-01-10.

What to do now

Contact the manufacturer if you require additional information.

Recall number

63807

Official notice

2022-01-10

The hazard

It was recently internally identified that five (5) lots of Simplexatm COVID-19 direct (Ref MOL4150) were shipped to Canada that had been manufactured with the recombinant hot start polymerase produced by Diasorin S.P.A. Instead of the enzyme from an external supplier. While the validation for the material made by Diasorin S.P.A. Had been successfully completed, the change had not yet been approved by Health Canada for use in products shipped to Canada patient results are not impacted by this compliance related issue. Recall start date: Jan 7, 2022

How to check if you're affected

Compare the product name and identifiers below with the item you own. Follow the official notice if they match.

Recall Numbers

63807

Checked manually this time?

The app alerts you when a new official recall is published — no searching, no checking back.

Turn on recall alerts

Affected products

Product 1

Affected Products - Simplexa Covid-19 Direct Assay, Lot or Serial Number - 12501N, 11269N, 13183N, 12348N, 11784N, Model or catalog number - MOL4150

Risk / hazard

It was recently internally identified that five (5) lots of Simplexatm COVID-19 direct (Ref MOL4150) were shipped to Canada that had been manufactured with the recombinant hot start polymerase produced by Diasorin S.P.A. Instead of the enzyme from an external supplier. While the validation for the material made by Diasorin S.P.A. Had been successfully completed, the change had not yet been approved by Health Canada for use in products shipped to Canada patient results are not impacted by this compliance related issue. Recall start date: Jan 7, 2022

Where it was sold

The source does not list specific retailers. See the official notice for where affected products were sold.

Location 1

CA · Canada

Affected area 1

CA · Canada

Company & contacts

Manufacturer

Not provided

Phone

Not provided

Brand: Diasorin Molecular, Simplexa Covid-19 Direct Assay.

Source & status

Source

Health Canada

Tier

official

Category

HEALTH

Classification

Type II

App estimate

medium

Recall details

Recall number

63807

Classification

Type II

Source tier

official

Documents, notices & source

See the official notice and source documents for full details.

View full official notice
Something wrong on this page?

Weekly recall digest

Get next week's recalls before you need them.

One email every Monday — official-source recalls for your country, and nothing else. Unsubscribe from any email.

The digest is the slow lane — one email a week. For instant, severity-gated alerts the moment a notice is published, get the app.

This recall was published 10 Jan 2022. The next one won't wait for you to search.

RecallScope watches official sources for the brands and VINs you follow, and alerts you the moment a new notice is published.